Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatment with Pyrilutamide, Minoxidil, and Finasteride showed improvement after 4 months. Shedding reduced, hair feels stronger and healthier, with no side effects.

A 35-year-old shared a 2-month update on their hair transplant of 3153 grafts, noting redness, itching, and some pimples, while using finasteride for over 12 years to maintain hair. Users discussed the effectiveness and timing of starting finasteride, with some suggesting consulting a doctor for young individuals considering the treatment.

KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.

OP saw positive results from 4 months of finasteride, vitamin D3, and microneedling. They plan to add rosemary and castor oil but decided against using minoxidil.

User tried oral min/fin/dut, VitD, and derma 2x monthly for hair loss and is happy with results. They saw improvements almost immediately.

The user started oral finasteride and minoxidil in November 2024, initially saw improvement, but has experienced increased shedding since April 2025. They are concerned the treatment may not be effective anymore and seek advice.

A user shared that taking multivitamins, specifically Myprotein "Alpha Man," improved their sexual energy while on finasteride. They believe the benefits come from Zinc and Vitamin B6/12.

The user discusses switching from multiple vitamins to a single multivitamin pill. They also mention using oral finasteride and topical minoxidil with finasteride for hair loss treatment.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

A user shared their positive experience with a 2,600 grafts hair transplant surgery in India, expressing optimism about the results. The conversation also debated the necessity of medications like finasteride to maintain hair transplant results and prevent further hair loss.

An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

People are humorously discussing unconventional and extreme methods of using hair loss treatments like finasteride and minoxidil, including vaping, snorting, and injecting. The conversation is filled with jokes and sarcasm about these methods.

The user is experiencing hair loss and is using Minoxidil once a day. They suspect Vitamin D deficiency and Seborrheic Dermatitis might be contributing factors.

Seborrheic dermatitis improved after a hair transplant. Effective treatments include Sebamed Anti-Dandruff Shampoo, Vichy Anti-Dandruff Shampoo, Nizoral, and medications like finasteride, dutasteride, and minoxidil.

A 23-year-old male experienced no shedding with RU58841 but switched to oral finasteride due to heart concerns, resulting in increased hair shedding. He is considering adding minoxidil to his regimen, which currently includes finasteride, Nizoral shampoo, and microneedling.

A satirical discussion on intentionally inducing hair loss using harmful habits and substances like cigarettes, junk food, anabolic steroids, and stress. The conversation humorously suggests extreme measures like chemotherapy and hydrofluoric acid, while also mentioning the ineffectiveness of sulfates and pumpkin seed oil in hair loss prevention.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.

The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.

A user shared their initial experiences with The Ordinary hair density serum, which contains Redensyl (taxifolin). They observed increased hair volume but also developed pimples, likely due to the serum stimulating sebaceous glands.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.